Closed System Drug Transfer Devices Market By Type (Membrane-To-Membrane Systems, and Needleless Systems), By Design Type (Barrier Type, and Filtration Type), By End User (Hospitals, and Clinics), Industry Trends, Estimation & Forecast, 2014-2025

Check Today's Best Price

$3500 Buy Now
The global Closed System Drug Transfer Devices market is valued at XX million US$ in 2018 is expected to reach 2421.17 million US$ by the end of 2025, growing at a CAGR of 10.34% during 2019-2025.
  • Market Overview

    The global Closed System Drug Transfer Devices market is valued at XX million US$ in 2018 is expected to reach 2421.17 million US$ by the end of 2025, growing at a CAGR of 10.34% during 2019-2025.

    Closed System Drug-Transfer Device (CSTD) is defined as a drug transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of the hazardous drug or vapor concentrations outside the system. American Society of Health System Pharmacists (ASHP) defined hazardous drugs as pharmaceuticals which display one or more of the following characteristics genotoxicity, carcinogenicity, teratogenicity or fertility impairment, or serious organ or other toxic manifestation at low doses in experimental animals or treated patients. The National Institute of Occupational Safety and Health (NIOSH) revised the definition in 2004 to include drugs that exhibit one or more of the following six characteristics in humans or animals: carcinogenicity, teratogenicity or other developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or structure and toxicity profiles of new drugs that mimic existing drugs determined hazardous by the other criteria.

    Closed System Drug Transfer Devices Market Value - 2016-2025

    Market Driver

    Increasing prevalence of cancer is the prime factor boosting the global closed system drug transfer devices market. For instance, according to Cancer Research U.K., more than 360,000 new cancer cases are registered in the UK every year. The incidence rates for all cancers combined are projected to rise by 2% in the UK between 2014 and 2035, to 742 cases per 100,000 people by 2035. In the U.K, there were around 183,000 new cancer cases in male and about 177,000 cancer cases in female, by 2015. Increase in prevalent cancer pool expands the diagnostic and treatment pool of cancer patients, thus demanding increased uptake of cancer treatments, including cytotoxic drugs, thereby boosting the demand for CSTDs.

    Increase in Global Cancer Incidence by Region 2012-2025-Million

    Market Restraint

    Lack of guidelines in emerging nations is one of the primary barrier hindering the entrenchment and high product demand for CSTDs in emerging nations. For instance, the healthcare statistics states that around 10 million healthcare personnel in China are exposed to hazardous drugs annually. In developing countries such as India, Brazil, Argentina, large volumes of health professionals are exposed to hazardous drugs. However, the usage rate of CSTDs is minimal in these nations due to non-compliance with safety standards. Developing nations hold a large untapped market potential for CSTDs,

    Segment Analysis

    Based on technology, the global Closed System Drug Transfer Devices market is broadly segmented as Membrane-To-Membrane Systems, and Needleless Systems. In 2018 Membrane-To-Membrane Systems is the dominant segment, and it accounts for approximately 50% of the market.

    Membrane-To-Membrane systems provide a double layer of protection for the safe transfer of hazardous drugs. It has a sealed expansion chamber that captures and retains hazardous drugs. Membrane-To-Membrane Systems has the largest share due to their ease of operation and the lower risk of contamination associated with double-membrane containment systems. Also, these systems use a double membrane junction between the syringe and the medication vial or container to help isolate medications. This double membrane containment system provides an added layer of protection compared to needleless membranes.

    Regional Analysis

    The global Closed System Drug Transfer Devices market is segmented into North America, Europe, South America, Asia Pacific, and ROW.

    North America is dominating the global Closed System Drug Transfer Devices market, due to the increasing incidence of cancer in the U.S. For instance, according to National Cancer Institute, in 2018, around 1,735,350 cases of cancer in the United States and 609,640 people are dead from the disease. The US is considered as a lucrative market for CSTDs due to high healthcare spending in this region. In 2016, total health care spending reached $3.4 trillion, increasing by 4.8% from 2015. By 2025, total healthcare care spending will account for 19.9% of GDP up from 17.8% in 2015, according to the CMS. Increased awareness of adverse effects due to hazardous drugs is created by healthcare agencies such as the National Institute for Occupational Safety and Health (NIOSH) and the Occupational Safety and Health Administration (OSHA). CSTDs was first introduced to the US in 1998. The first approved CSTD was Phaseal. Currently, there are multiple CSTDs available in the US market. These include – Spiros, Texium with Smart Site, On Guard with Tevadaptor, ChemoClave, Equashield, ChemoLock, Vialshield, Halo and Arisure.

    The North America Closed System Drug Transfer Devices market size was XX million USD in 2018, and it will be 1376.70 million USD in 2025, with a CAGR 11.64% from 2019 to 2025.

    Europe is the second-largest market for Closed System Drug Transfer Devices in 2018, as the region has the presence of multiple government and non-government associations and organizations which focus on the awareness of safe handling of cytotoxic drugs such as European Agency for Safety and Health at Work (EU-OSHA), European Society of Oncology Pharmacy. For instance, In November 2015, the European Parliament (EP) formed a Commission to take action on chemical risk factors, including exposure to hazardous drugs. And in April 2016, the EP launched new policy recommendations on preventing occupational exposure to cytotoxic drugs as an initiative designed to protect healthcare professionals working across the EU.

    Competitive Analysis

    The major players include BD Medical, Inc, ICU Medical, Inc, Equashield, LLC, Corvida Medical, Teva Medical Ltd, Hospira, and others.

    The increasing launch of new Closed System Drug Transfer Devices is boosting the global Closed System Drug Transfer Devices market. For instance, October 9, 2018, ICU Medical, Inc., a worldwide leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications, have introduced the Diana ChemoLock Transfer Set for use with the Diana Compounding Workflow System has received United States Food and Drug Administration (FDA) 510K clearance. The Diana ChemoLock Transfer Set is a sterile, single-use closed system transfer device (CSTD) used to transfer drugs from a drug vial to an IV bag for intravenous drug administration. Moreover, in February 16, 2018, Baxter International Inc., a leader in innovative technology for medication delivery, have signed a distribution agreement for the U.S. launch of the Arisure Closed System Transfer device, which consists of several components that work together to help prevent contaminants from entering the intravenous (IV) medication delivery system and the escape of hazardous substances out of the system during drug preparation and administration.

    Global Closed System Drug Transfer Devices Market

    • Consumption by Regions
      • North America
      • Europe
      • South America
      • Asia Pacific
      • ROW
    • Segment by Type
      • Membrane-To-Membrane Systems
      • Needleless Systems
    • Segment by Design Type
      • Barrier Type
      • Filtration Type
    • Segment by End User
      • Hospitals
      • Clinics
    keyboard_arrow_up
  • Table of Content

    1. Market Introduction
    1.1. Executive Summary
    1.2. Market Definition
    1.3. Market Scope

    2. Research Methodology
    2.1. Primary Research
    2.2. Research Methodology
    2.3. Assumptions & Exclusions
    2.4. Secondary data sources

    3. Closed System Drug Transfer Devices Market Overview
    3.1. Report Segmentation & Scope
    3.2. Key Market Trend
    3.3. Drivers
    3.3.1. Increasing prevalence of cancer
    3.4. Restraints
    3.4.1. Lack of relevant guidelines in emerging nations
    3.5. Opportunity
    3.5.1. Untapped market potential in developing nations
    3.6. Porter’s Five Forces Analysis
    3.6.1. Porter’s Five Forces Analysis
    3.7. Market Share Analysis

    4. Type Overview
    4.1. Introduction
    4.1.1. Market Size & Forecast
    4.2. Membrane-To-Membrane Systems
    4.2.1. Market Size & Forecast
    4.3. Needleless Systems
    4.3.1. Market Size & Forecast

    5. Design Type Overview
    5.1. Introduction
    5.1.1. Market Size & Forecast
    5.2. Barrier Type
    5.2.1. Market Size & Forecast
    5.3. Filtration Type
    5.3.1. Market Size & Forecast

    6. End User Overview
    6.1. Introduction
    6.1.1. Market Size & Forecast
    6.2. Hospitals
    6.2.1. Market Size & Forecast
    6.3. Clinics
    6.3.1. Market Size & Forecast

    7. Closed System Drug Transfer Devices Market Regional Overview
    7.1. Introduction
    7.1.1. Market Size & Forecast
    7.2. North America Closed System Drug Transfer Devices Market
    7.2.1. North America Market Size & Forecast, By Country
    7.2.2. North America Market Size & Forecast, By Type
    7.2.3. North America Market Size & Forecast, By Design Type
    7.2.4. North America Market Size & Forecast, By End User
    7.2.5. U.S.
    7.2.5.1. Market Size and Forecast
    7.2.6. Canada
    7.2.6.1. Market Size and Forecast
    7.2.7. Mexico
    7.2.7.1. Market Size and Forecast
    7.3. Europe Closed System Drug Transfer Devices Market
    7.3.1. Europe Market Size & Forecast, By Country
    7.3.2. Europe Market Size & Forecast, By Type
    7.3.3. Europe Market Size & Forecast, By Design Type
    7.3.4. Europe Market Size & Forecast, By End User
    7.3.5. Germany
    7.3.5.1. Market Size and Forecast
    7.3.6. France
    7.3.6.1. Market Size and Forecast
    7.3.7. UK
    7.3.7.1. Market Size and Forecast
    7.3.8. Italy
    7.3.8.1. Market Size and Forecast
    7.3.9. Spain
    7.3.9.1. Market Size and Forecast
    7.3.10. Rest of Europe
    7.3.10.1. Market Size and Forecast
    7.4. Asia-Pacific Closed System Drug Transfer Devices Market
    7.4.1. Asia-Pacific Market Size & Forecast, By Country
    7.4.2. Asia-Pacific Market Size & Forecast, By Type
    7.4.3. Asia-Pacific Market Size & Forecast, By Design Type
    7.4.4. Asia-Pacific Market Size & Forecast, By End User
    7.4.5. Japan
    7.4.5.1. Market Size and Forecast
    7.4.6. China
    7.4.6.1. Market Size and Forecast
    7.4.7. Australia
    7.4.7.1. Market Size and Forecast
    7.4.8. India
    7.4.8.1. Market Size and Forecast
    7.4.9. South Korea
    7.4.9.1. Market Size and Forecast
    7.4.10. Rest of Asia-Pacific
    7.4.10.1. Market Size and Forecast
    7.5. South America Closed System Drug Transfer Devices Market
    7.5.1. South America Market Size & Forecast, By Country
    7.5.2. South America Market Size & Forecast, By Type
    7.5.3. South America Market Size & Forecast, By Design Type
    7.5.4. South America Market Size & Forecast, By End User
    7.5.5. Brazil
    7.5.5.1. Market Size and Forecast
    7.5.6. Argentina
    7.5.6.1. Market Size and Forecast
    7.5.7. Rest of South America
    7.5.7.1. Market Size and Forecast
    7.6. Middle East & Africa Closed System Drug Transfer Devices Market
    7.6.1. Middle East & Africa Market Size & Forecast, By Country
    7.6.2. Middle East & Africa Market Size & Forecast, By Type
    7.6.3. Middle East & Africa Market Size & Forecast, By Design Type
    7.6.4. Middle East & Africa Market Size & Forecast, By End User
    7.6.5. GCC Countries
    7.6.5.1. Market Size and Forecast
    7.6.6. Egypt
    7.6.6.1. Market Size and Forecast
    7.6.7. South Africa
    7.6.7.1. Market Size and Forecast
    7.6.8. Rest of Middle East & Africa
    7.6.8.1. Market Size and Forecast

    8. Company Profile
    8.1. BD Medical, Inc
    8.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    8.1.2. BD Medical, Inc Product Category, Application, and Specification
    8.1.3. BD Medical, Inc Financial Performance (2016-2018)
    8.1.4. Main Business/Business Overview
    8.2. ICU Medical, Inc
    8.3. Equashield, LLC
    8.4. Corvida Medical
    8.5. Teva Medical Ltd
    8.6. Hospira

    keyboard_arrow_up
    • The following manufacturers are covered:
      • BD Medical, Inc
      • ICU Medical, Inc
      • Equashield, LLC
      • Corvida Medical
      • Teva Medical Ltd
      • Hospira
    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CLIENTS